BOOTH #331
Myriad is excited to officially unveil the FirstGene® Multiple Prenatal Screen, the next generation of prenatal screening. Join us for an up-close look at this revolutionary screen and discover how the FirstGene® screen is simplifying and streamlining the screening process.
Learn more about The FirstGene® Screen
INTRODUCING THE FIRSTGENE® SCREEN
Coordinating multiple prenatal screens individually can be frustrating for busy clinicians and patients alike. With the FirstGene® Multiple Prenatal Screen, you can now perform multiple screens in one, from one blood draw, and receive a single comprehensive report full of actionable genetic insights. The FirstGene® screen streamlines your workflow and enables patients to know more sooner about risks that may affect the health of their pregnancy.
Assesses the carrier status of the pregnant individual for 20 recessive conditions with a >99% analytical sensitivity and specificity.1
Assesses fetal risk for common and serious aneuploidies with >99%1 analytical sensitivity and specificity. Screen includes:
Assesses fetal risk for the inheritance of 19 common, actionable conditions with a >98% analytical sensitivity and >99% analytical specificity.1 No paternal sample needed.
Assesses RhD compatibility between the pregnant person and the fetus with >99% sensitivity and specificity for copy number variant calling.1
VISIT THE MYRIAD GENETICS BOOTH #331
Just how much simpler is FirstGene® Multiple Prenatal Screen than the current state of prenatal screening? Visit our booth to find out. Take the Claw Machine Challenge and experience firsthand the game-changing precision, speed, and simplicity of the FirstGene® screen. And after you play, enjoy some Dippin’ Dots on us!
Industry-Hosted Symposium Details
How do emerging prenatal screening technologies perform in real clinical scenarios? This session introduces FirstGene® Multiple Prenatal Screen, a single‑draw prenatal screen designed to assess multiple genetic risks at once, followed by case examples. Attendees will gain insight into the test design, including the next advancements to our proprietary AMPLIFY® technology. You'll learn how these integrated results may help address common challenges such as unavailable partner testing and complex carrier scenarios.
Register for the FirstGene screen industry-hosted symposium in the conference app
Meet our presenters:
Dale Muzzey
PhD, Chief Scientific OfficerMyriad Genetics
Dallas Reed
MD, FACMG, FACOG, Principal MedicalAdvisor, Myriad Genetics
Did you know?
1 in 4womenin an OB-GYN setting meet criteria for hereditary cancer testing.2
hereditary cancer risk assessment and care planning
The MyRisk® Hereditary Cancer Test with RiskScore® evaluates 63 guideline-recommended genes associated with hereditary cancer risk. This complete solution identifies whether patients with a personal or family history of certain cancers are at increased risk, empowering providers to personalize care and prevention plans.
Visit booth #331 to learn more about MyRisk®
Request more information about Myriad's prenatal and hereditary cancer screening.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
Identifies couples at risk to pass down serious, prevalent, clinically actionable inherited conditions
Assesses fetal risk for common conditions and more as early as 8 weeks gestation, and delivers insights that support faster, more comprehensive care
Detects predicted sex as early as six weeks into pregnancy
Identifies if a pregnancy is at an increased risk for a wide variety of chromosomal conditions as early as eight weeks
Evaluates genes associated with hereditary cancer risk and identifies whether patients are at increased risk for certain cancers